{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:53:15Z","timestamp":1740163995064,"version":"3.37.3"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Genzada Pharmecuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL). Despite having a wide variety of therapeutic agents available for the treatment of MF, patients often suffer from a significant decrease in quality of life and rarely achieve long-term remission or complete cure, highlighting a need to develop novel therapeutic agents for this disease. The present study was undertaken to evaluate the efficacy of a novel anti-tumor agent, GZ17-6.02, which is composed of curcumin, harmine, and isovanillin, against MF in vitro and in murine models. Treatment of HH and MyLa cells with GZ17-6.02 inhibited the growth of both cell lines with IC50\u2009\u00b1\u2009standard errors for growth inhibition of 14.37\u2009\u00b1\u20091.19\u00a0\u00b5g\/mL and 14.56\u2009\u00b1\u20091.35\u00a0\u00b5g\/mL, respectively, and increased the percentage of cells in late apoptosis (<jats:italic>p<\/jats:italic>\u2009=\u2009.0304 for HH; <jats:italic>p<\/jats:italic>\u2009=\u2009.0301 for MyLa). Transcriptomic and proteomic analyses revealed that GZ17-6.02 suppressed several pathways, including tumor necrosis factor (TNF)-\u0251 signaling via nuclear factor (NF)-kB, mammalian target of rapamycin complex (mTORC)1, and Pi3K\/Akt\/mTOR signaling. In a subcutaneous tumor model, GZ17-6.02 decreased tumor volume (<jats:italic>p<\/jats:italic>\u2009=\u2009.002) and weight (<jats:italic>p<\/jats:italic>\u2009=\u2009.009) compared to control conditions. Proteomic analysis of tumor samples showed that GZ17-6.02 suppressed the expression of several proteins that may promote CTCL growth, including mitogen-activated protein kinase (MAPK)1, MAPK3, Growth factor receptor bound protein (GRB)2, and Mediator of RAP80 interactions and targeting subunit of 40\u00a0kDa (MERIT)40.<\/jats:p>","DOI":"10.1038\/s41598-024-52544-z","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T06:01:41Z","timestamp":1705989701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8833-6080","authenticated-orcid":false,"given":"Zachary A.","family":"Bordeaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-7594","authenticated-orcid":false,"given":"Sriya V.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8388-6876","authenticated-orcid":false,"given":"Justin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-3696","authenticated-orcid":false,"given":"Gabriella","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-7020","authenticated-orcid":false,"given":"Jaimie","family":"McKeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1539-2708","authenticated-orcid":false,"given":"Weiying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2463-9438","authenticated-orcid":false,"given":"Selina M.","family":"Yossef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-6659","authenticated-orcid":false,"given":"Emily Z.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-9165","authenticated-orcid":false,"given":"Cameron E.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-1515","authenticated-orcid":false,"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-8852","authenticated-orcid":false,"given":"Madan M.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"52544_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","volume":"7","author":"R Dummer","year":"2021","unstructured":"Dummer, R. et al. Cutaneous T cell lymphoma. Nat. Rev. Dis. Primers 7, 61. https:\/\/doi.org\/10.1038\/s41572-021-00296-9 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"52544_CR2","doi-asserted-by":"publisher","first-page":"223.e221-217","DOI":"10.1016\/j.jaad.2013.08.033","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A. & Querfeld, C. Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part II. Prognosis, management, and future directions. J. Am. Acad. Dermatol. 70, 223.e221\u2013217. https:\/\/doi.org\/10.1016\/j.jaad.2013.08.033 (2014) (quiz 240-222).","journal-title":"J. Am. Acad. Dermatol."},{"key":"52544_CR3","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/jco.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar, N. S. et al. Survival outcomes and prognostic factors in mycosis fungoides\/s\u00e9zary syndrome: Validation of the Revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer Staging Proposal. J. Clin. Oncol. 28, 4730\u20134739. https:\/\/doi.org\/10.1200\/jco.2009.27.7665 (2010).","journal-title":"J. Clin. Oncol."},{"key":"52544_CR4","doi-asserted-by":"publisher","first-page":"adv00013","DOI":"10.2340\/00015555-3367","volume":"100","author":"A Maguire","year":"2020","unstructured":"Maguire, A. et al. Early-stage mycosis fungoides: Epidemiology and prognosis. Acta Derm. Venereol. 100, adv00013. https:\/\/doi.org\/10.2340\/00015555-3367 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"52544_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1085-5629(00)80005-x","volume":"19","author":"MS Howard","year":"2000","unstructured":"Howard, M. S. & Smoller, B. R. Mycosis fungoides: Classic disease and variant presentations. Semin Cutan Med. Surg. 19, 91\u201399. https:\/\/doi.org\/10.1016\/s1085-5629(00)80005-x (2000).","journal-title":"Semin Cutan Med. Surg."},{"key":"52544_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.hoc.2018.09.001","volume":"33","author":"C Larocca","year":"2019","unstructured":"Larocca, C. & Kupper, T. Mycosis fungoides and s\u00e9zary syndrome: An update. Hematol. Oncol. Clin. North. Am. 33, 103\u2013120. https:\/\/doi.org\/10.1016\/j.hoc.2018.09.001 (2019).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"52544_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.006","author":"J Choi","year":"2021","unstructured":"Choi, J. et al. Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides: A cross-sectional analysis of the 2012\u20132017 National Inpatient Sample. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.006 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"52544_CR8","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/cncr.22252","volume":"107","author":"MF Demierre","year":"2006","unstructured":"Demierre, M. F., Gan, S., Jones, J. & Miller, D. R. Significant impact of cutaneous T-cell lymphoma on patients\u2019 quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 107, 2504\u20132511. https:\/\/doi.org\/10.1002\/cncr.22252 (2006).","journal-title":"Cancer"},{"key":"52544_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","volume":"9","author":"R Ottevanger","year":"2022","unstructured":"Ottevanger, R. et al. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 9, 57\u201364. https:\/\/doi.org\/10.1016\/j.jdin.2022.07.007 (2022).","journal-title":"JAAD Int."},{"key":"52544_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7010001","author":"S Kaul","year":"2019","unstructured":"Kaul, S. et al. Comorbidities in mycosis fungoides and racial differences in co-existent lymphomatoid papulosis: A cross-sectional study of 580 patients in an urban tertiary care center. Medicines https:\/\/doi.org\/10.3390\/medicines7010001 (2019).","journal-title":"Medicines"},{"key":"52544_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jnma.2019.08.006","volume":"111","author":"AH Huang","year":"2019","unstructured":"Huang, A. H. et al. Racial disparities in the clinical presentation and prognosis of patients with mycosis fungoides. J. Natl. Med. Assoc. 111, 633\u2013639. https:\/\/doi.org\/10.1016\/j.jnma.2019.08.006 (2019).","journal-title":"J. Natl. Med. Assoc."},{"key":"52544_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ejp.760","volume":"20","author":"B Rowe","year":"2016","unstructured":"Rowe, B. & Yosipovitch, G. Malignancy-associated pruritus. Eur. J. Pain 20, 19\u201323. https:\/\/doi.org\/10.1002\/ejp.760 (2016).","journal-title":"Eur. J. Pain"},{"key":"52544_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger, F. et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2017. Eur. J. Cancer 77, 57\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.027 (2017).","journal-title":"Eur. J. Cancer"},{"key":"52544_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bjh.17458","volume":"195","author":"TK Sethi","year":"2021","unstructured":"Sethi, T. K., Montanari, F., Foss, F. & Reddy, N. How we treat advanced stage cutaneous T-cell lymphoma\u2014mycosis fungoides and S\u00e9zary syndrome. Br. J. Haematol. 195, 352\u2013364. https:\/\/doi.org\/10.1111\/bjh.17458 (2021).","journal-title":"Br. J. Haematol."},{"key":"52544_CR15","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/nejm198912283212603","volume":"321","author":"FJ Kaye","year":"1989","unstructured":"Kaye, F. J. et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med. 321, 1784\u20131790. https:\/\/doi.org\/10.1056\/nejm198912283212603 (1989).","journal-title":"N. Engl. J. Med."},{"key":"52544_CR16","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze, R., Hodak, E., Zinzani, P. L., Specht, L. & Ladetto, M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv30\u2013iv40. https:\/\/doi.org\/10.1093\/annonc\/mdy133 (2018).","journal-title":"Ann. Oncol."},{"key":"52544_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-020-00809-w","volume":"22","author":"H Kamijo","year":"2021","unstructured":"Kamijo, H. & Miyagaki, T. Mycosis fungoides and s\u00e9zary syndrome: Updates and review of current therapy. Curr. Treat Options Oncol. 22, 10. https:\/\/doi.org\/10.1007\/s11864-020-00809-w (2021).","journal-title":"Curr. Treat Options Oncol."},{"key":"52544_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12788\/j.sder.2018.002","volume":"37","author":"L Cerroni","year":"2018","unstructured":"Cerroni, L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med. Surg. 37, 2\u201310. https:\/\/doi.org\/10.12788\/j.sder.2018.002 (2018).","journal-title":"Semin Cutan Med. Surg."},{"key":"52544_CR19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.18632\/oncotarget.26704","volume":"10","author":"C Ghosh","year":"2019","unstructured":"Ghosh, C. et al. Super-enhancers: Novel target for pancreatic ductal adenocarcinoma. Oncotarget 10, 1554\u20131571. https:\/\/doi.org\/10.18632\/oncotarget.26704 (2019).","journal-title":"Oncotarget"},{"key":"52544_CR20","doi-asserted-by":"publisher","first-page":"12163","DOI":"10.1038\/s41598-018-29683-1","volume":"8","author":"V Vishwakarma","year":"2018","unstructured":"Vishwakarma, V. et al. Potent antitumor effects of a combination of three nutraceutical compounds. Sci. Rep. 8, 12163. https:\/\/doi.org\/10.1038\/s41598-018-29683-1 (2018).","journal-title":"Sci. Rep."},{"key":"52544_CR21","doi-asserted-by":"publisher","first-page":"656453","DOI":"10.3389\/fonc.2021.656453","volume":"11","author":"L Booth","year":"2021","unstructured":"Booth, L., West, C., Von Hoff, D., Kirkwood, J. M. & Dent, P. GZ17\u20136.02 Interacts With [MEK1\/2 and B-RAF Inhibitors] to Kill Melanoma Cells. Front. Oncol. 11, 656453. https:\/\/doi.org\/10.3389\/fonc.2021.656453 (2021).","journal-title":"Front. Oncol."},{"key":"52544_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.18632\/oncotarget.28177","volume":"13","author":"L Booth","year":"2022","unstructured":"Booth, L., West, C., Moore, R. P., Von Hoff, D. & Dent, P. GZ17-6.02 and palbociclib interact to kill ER + breast cancer cells. Oncotarget 13, 92\u2013104. https:\/\/doi.org\/10.18632\/oncotarget.28177 (2022).","journal-title":"Oncotarget"},{"key":"52544_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084174","author":"J Choi","year":"2022","unstructured":"Choi, J. et al. GZ17-6.02 inhibits the growth of EGFRvIII + Glioblastoma. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23084174 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"52544_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18632\/oncotarget.28189","volume":"13","author":"L Booth","year":"2022","unstructured":"Booth, L., West, C., Moore, R. P., Hoff, D. V. & Dent, P. GZ17-6.02 and axitinib interact to kill renal carcinoma cells. Oncotarget 13, 281\u2013290. https:\/\/doi.org\/10.18632\/oncotarget.28189 (2022).","journal-title":"Oncotarget"},{"key":"52544_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001425","author":"ZA Bordeaux","year":"2023","unstructured":"Bordeaux, Z. A., Kwatra, S. G., Booth, L. & Dent, P. A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations. Anticancer Drugs https:\/\/doi.org\/10.1097\/cad.0000000000001425 (2023).","journal-title":"Anticancer Drugs"},{"key":"52544_CR26","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.xjidi.2023.100206","volume":"3","author":"ZA Bordeaux","year":"2023","unstructured":"Bordeaux, Z. A. et al. Topical GZ21T inhibits the growth of actinic keratoses in a UVB-induced model of skin carcinogenesis. JID Innov. 3, 100206. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100206 (2023).","journal-title":"JID Innov."},{"key":"52544_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2009.04.037","volume":"285","author":"SS Lin","year":"2009","unstructured":"Lin, S. S. et al. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett. 285, 127\u2013133. https:\/\/doi.org\/10.1016\/j.canlet.2009.04.037 (2009).","journal-title":"Cancer Lett."},{"key":"52544_CR28","first-page":"2125","volume":"30","author":"SH Wu","year":"2010","unstructured":"Wu, S. H. et al. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res. 30, 2125\u20132133 (2010).","journal-title":"Anticancer Res."},{"key":"52544_CR29","first-page":"1050","volume":"21","author":"A Unlu","year":"2016","unstructured":"Unlu, A., Nayir, E., Dogukan Kalenderoglu, M., Kirca, O. & Ozdogan, M. Curcumin (Turmeric) and cancer. J. Buon 21, 1050\u20131060 (2016).","journal-title":"J. Buon"},{"key":"52544_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020399","author":"P Maiti","year":"2019","unstructured":"Maiti, P., Scott, J., Sengupta, D., Al-Gharaibeh, A. & Dunbar, G. L. Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt\/mTOR pathway in cultured glioblastoma cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20020399 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"52544_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/sj.onc.1209019","volume":"25","author":"A Chen","year":"2006","unstructured":"Chen, A., Xu, J. & Johnson, A. C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25, 278\u2013287. https:\/\/doi.org\/10.1038\/sj.onc.1209019 (2006).","journal-title":"Oncogene"},{"key":"52544_CR32","first-page":"6438","volume":"7","author":"L Zhen","year":"2014","unstructured":"Zhen, L. et al. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways. Int. J. Clin. Exp. Pathol. 7, 6438\u20136446 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"52544_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3892\/ol.2020.12167","volume":"20","author":"AGX Trochopoulos","year":"2020","unstructured":"Trochopoulos, A. G. X. et al. Antineoplastic effect of a novel nanosized curcumin on cutaneous T cell lymphoma. Oncol. Lett. 20, 304. https:\/\/doi.org\/10.3892\/ol.2020.12167 (2020).","journal-title":"Oncol. Lett."},{"key":"52544_CR34","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/jid.2010.86","volume":"130","author":"C Zhang","year":"2010","unstructured":"Zhang, C. et al. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients\u2019 PBMCs: Potential role for STAT-3 and NF-kappaB signaling. J. Invest. Dermatol. 130, 2110\u20132119. https:\/\/doi.org\/10.1038\/jid.2010.86 (2010).","journal-title":"J. Invest. Dermatol."},{"key":"52544_CR35","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1172\/JCI63623","volume":"123","author":"N Pozo","year":"2013","unstructured":"Pozo, N. et al. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J. Clin. Investig. 123, 2475\u20132487. https:\/\/doi.org\/10.1172\/JCI63623 (2013).","journal-title":"J. Clin. Investig."},{"key":"52544_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080803","author":"JC Chamcheu","year":"2019","unstructured":"Chamcheu, J. C. et al. Role and therapeutic targeting of the PI3K\/Akt\/mTOR signaling pathway in skin cancer: A review of current status and future trends on natural and synthetic agents therapy. Cells https:\/\/doi.org\/10.3390\/cells8080803 (2019).","journal-title":"Cells"},{"key":"52544_CR37","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3892\/or.2017.5952","volume":"38","author":"J Gao","year":"2017","unstructured":"Gao, J. et al. Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK\/CREB pathway. Oncol. Rep. 38, 2927\u20132934. https:\/\/doi.org\/10.3892\/or.2017.5952 (2017).","journal-title":"Oncol. Rep."},{"key":"52544_CR38","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s12272-020-01283-6","volume":"43","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Li, D. & Yu, S. Pharmacological effects of harmine and its derivatives: A review. Arch Pharm. Res. 43, 1259\u20131275. https:\/\/doi.org\/10.1007\/s12272-020-01283-6 (2020).","journal-title":"Arch Pharm. Res."},{"key":"52544_CR39","doi-asserted-by":"publisher","first-page":"e0247652","DOI":"10.1371\/journal.pone.0247652","volume":"16","author":"E Nafie","year":"2021","unstructured":"Nafie, E. et al. Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1. PLoS ONE 16, e0247652. https:\/\/doi.org\/10.1371\/journal.pone.0247652 (2021).","journal-title":"PLoS ONE"},{"key":"52544_CR40","first-page":"2612","volume":"12","author":"J He","year":"2022","unstructured":"He, J. et al. Harmine suppresses breast cancer cell migration and invasion by regulating TAZ-mediated epithelial-mesenchymal transition. Am. J. Cancer Res. 12, 2612\u20132626 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"52544_CR41","doi-asserted-by":"publisher","first-page":"D91","DOI":"10.1093\/nar\/gkr895","volume":"40","author":"PJ Kersey","year":"2012","unstructured":"Kersey, P. J. et al. Ensembl genomes: An integrative resource for genome-scale data from non-vertebrate species. Nucleic Acids Res. 40, D91-97. https:\/\/doi.org\/10.1093\/nar\/gkr895 (2012).","journal-title":"Nucleic Acids Res."},{"key":"52544_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635 (2013).","journal-title":"Bioinformatics"},{"key":"52544_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"52544_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115\u2013121. https:\/\/doi.org\/10.1038\/nmeth.3252 (2015).","journal-title":"Nat. Methods"},{"key":"52544_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genetics 34, 267\u2013273. https:\/\/doi.org\/10.1038\/ng1180 (2003).","journal-title":"Nat. Genetics"},{"key":"52544_CR46","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52544_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."},{"key":"52544_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 14, 7. https:\/\/doi.org\/10.1186\/1471-2105-14-7 (2013).","journal-title":"BMC Bioinform."},{"key":"52544_CR49","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. EnrichR: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90-97. https:\/\/doi.org\/10.1093\/nar\/gkw377 (2016).","journal-title":"Nucleic Acids Res."},{"key":"52544_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. EnrichR: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128. https:\/\/doi.org\/10.1186\/1471-2105-14-128 (2013).","journal-title":"BMC Bioinform."},{"key":"52544_CR51","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with EnrichR. Curr. Protoc. 1, e90. https:\/\/doi.org\/10.1002\/cpz1.90 (2021).","journal-title":"Curr. Protoc."},{"key":"52544_CR52","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jid.2019.08.454","volume":"140","author":"A Bresin","year":"2020","unstructured":"Bresin, A. et al. Preclinical evidence for targeting PI3K\/mTOR signaling with dual-inhibitors as a therapeutic strategy against cutaneous T-cell lymphoma. J. Invest. Dermatol. 140, 1045-1053.e1046. https:\/\/doi.org\/10.1016\/j.jid.2019.08.454 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"52544_CR53","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1600-0625.2010.01138.x","volume":"19","author":"T Krejsgaard","year":"2010","unstructured":"Krejsgaard, T. et al. A novel xenograft model of cutaneous T-cell lymphoma. Exp. Dermatol. 19, 1096\u20131102. https:\/\/doi.org\/10.1111\/j.1600-0625.2010.01138.x (2010).","journal-title":"Exp. Dermatol."},{"key":"52544_CR54","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1182\/blood-2014-05-571778","volume":"125","author":"Y Huang","year":"2015","unstructured":"Huang, Y., Su, M. W., Jiang, X. & Zhou, Y. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma. Blood 125, 1435\u20131443. https:\/\/doi.org\/10.1182\/blood-2014-05-571778 (2015).","journal-title":"Blood"},{"key":"52544_CR55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/0092-8674(95)90541-3","volume":"81","author":"M Tewari","year":"1995","unstructured":"Tewari, M. et al. Yama\/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801\u2013809. https:\/\/doi.org\/10.1016\/0092-8674(95)90541-3 (1995).","journal-title":"Cell"},{"key":"52544_CR56","first-page":"3976","volume":"53","author":"SH Kaufmann","year":"1993","unstructured":"Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E. & Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 53, 3976\u20133985 (1993).","journal-title":"Cancer Res."},{"key":"52544_CR57","first-page":"3119","volume":"11","author":"D Gao","year":"2018","unstructured":"Gao, D., Sun, H., Zhu, J., Tang, Y. & Li, S. CXCL12 induces migration of Schwann cells via p38 MAPK and autocrine of CXCL12 by the CXCR4 receptor. Int. J. Clin. Exp. Pathol. 11, 3119\u20133125 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"52544_CR58","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.3892\/or.2014.3536","volume":"32","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. Activation of STAT3 is involved in malignancy mediated by CXCL12\u2013CXCR4 signaling in human breast cancer. Oncol. Rep. 32, 2760\u20132768. https:\/\/doi.org\/10.3892\/or.2014.3536 (2014).","journal-title":"Oncol. Rep."},{"key":"52544_CR59","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood-2011-06-364828","volume":"119","author":"Y Zoughlami","year":"2012","unstructured":"Zoughlami, Y. et al. Regulation of CXCR4 conformation by the small GTPase Rac1: Implications for HIV infection. Blood 119, 2024\u20132032. https:\/\/doi.org\/10.1182\/blood-2011-06-364828 (2012).","journal-title":"Blood"},{"key":"52544_CR60","doi-asserted-by":"publisher","first-page":"1045459","DOI":"10.3389\/fonc.2022.1045459","volume":"12","author":"L Booth","year":"2022","unstructured":"Booth, L., Roberts, J. L., West, C. & Dent, P. GZ17-6.02 kills prostate cancer cells in vitro and in vivo. Front. Oncol. 12, 1045459. https:\/\/doi.org\/10.3389\/fonc.2022.1045459 (2022).","journal-title":"Front. Oncol."},{"key":"52544_CR61","doi-asserted-by":"publisher","first-page":"711043","DOI":"10.3389\/fonc.2021.711043","volume":"11","author":"L Booth","year":"2021","unstructured":"Booth, L., West, C., Moore, R. P., Von Hoff, D. & Dent, P. GZ17\u20136.02 and pemetrexed interact to kill osimertinib-resistant NSCLC cells that express mutant ERBB1 proteins. Front. Oncol. 11, 711043. https:\/\/doi.org\/10.3389\/fonc.2021.711043 (2021).","journal-title":"Front. Oncol."},{"key":"52544_CR62","doi-asserted-by":"publisher","first-page":"677725","DOI":"10.3389\/fonc.2021.677725","volume":"11","author":"L Booth","year":"2021","unstructured":"Booth, L., West, C., Von Hoff, D. & Dent, P. Corrigendum: GZ17-6.02 and doxorubicin interact to kill sarcoma cells via autophagy and death receptor signaling. Front. Oncol. 11, 677725. https:\/\/doi.org\/10.3389\/fonc.2021.677725 (2021).","journal-title":"Front. Oncol."},{"key":"52544_CR63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd2871","volume":"8","author":"PA J\u00e4nne","year":"2009","unstructured":"J\u00e4nne, P. A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709\u2013723. https:\/\/doi.org\/10.1038\/nrd2871 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"52544_CR64","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/CAD.0000000000001425","volume":"34","author":"ZA Bordeaux","year":"2022","unstructured":"Bordeaux, Z. A., Kwatra, S. G., Booth, L. & Dent, P. A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations. Anti-cancer Drugs 34(4), 544 (2022).","journal-title":"Anti-cancer Drugs"},{"key":"52544_CR65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1254\/jphs.12149fp","volume":"121","author":"Q Qiao","year":"2013","unstructured":"Qiao, Q., Jiang, Y. & Li, G. Inhibition of the PI3K\/AKT-NF-\u03baB pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt\u2019s lymphoma. J. Pharmacol. Sci. 121, 247\u2013256. https:\/\/doi.org\/10.1254\/jphs.12149fp (2013).","journal-title":"J. Pharmacol. Sci."},{"key":"52544_CR66","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/ptr.6780","volume":"34","author":"GA Borges","year":"2020","unstructured":"Borges, G. A. et al. Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells. Phytother. Res. 34, 3311\u20133324. https:\/\/doi.org\/10.1002\/ptr.6780 (2020).","journal-title":"Phytother. Res."},{"key":"52544_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00484","author":"S Kuttikrishnan","year":"2019","unstructured":"Kuttikrishnan, S. et al. Curcumin induces apoptotic cell death via inhibition of PI3-kinase\/AKT pathway in B-precursor acute lymphoblastic leukemia. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00484 (2019).","journal-title":"Front. Oncol."},{"key":"52544_CR68","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/bph.12131","volume":"169","author":"BB Aggarwal","year":"2013","unstructured":"Aggarwal, B. B., Gupta, S. C. & Sung, B. Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br. J. Pharmacol. 169, 1672\u20131692. https:\/\/doi.org\/10.1111\/bph.12131 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"52544_CR69","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1182\/blood.V110.11.1177.1177","volume":"110","author":"S Vadhan-Raj","year":"2007","unstructured":"Vadhan-Raj, S. et al. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase I\/II study. Blood 110, 1177. https:\/\/doi.org\/10.1182\/blood.V110.11.1177.1177 (2007).","journal-title":"Blood"},{"key":"52544_CR70","first-page":"49","volume":"11","author":"YX Xu","year":"1997","unstructured":"Xu, Y. X., Pindolia, K. R., Janakiraman, N., Chapman, R. A. & Gautam, S. C. Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol. Mol. Hematol. 11, 49\u201362 (1997).","journal-title":"Hematopathol. Mol. Hematol."},{"key":"52544_CR71","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3389\/fonc.2020.01331","volume":"10","author":"L Booth","year":"2020","unstructured":"Booth, L., West, C., Hoff, D. V. & Dent, P. GZ17-6.02 and doxorubicin interact to kill sarcoma cells via autophagy and death receptor signaling. Front. Oncol. 10, 1331. https:\/\/doi.org\/10.3389\/fonc.2020.01331 (2020).","journal-title":"Front. Oncol."},{"key":"52544_CR72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fonc.2012.00109","volume":"2","author":"B Weigelt","year":"2012","unstructured":"Weigelt, B. & Downward, J. Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol. 2, 109. https:\/\/doi.org\/10.3389\/fonc.2012.00109 (2012).","journal-title":"Front. Oncol."},{"key":"52544_CR73","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: Navigating the network. Cell 169, 381\u2013405. https:\/\/doi.org\/10.1016\/j.cell.2017.04.001 (2017).","journal-title":"Cell"},{"key":"52544_CR74","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2013.04.027","volume":"69","author":"G Levidou","year":"2013","unstructured":"Levidou, G. et al. A comprehensive immunohistochemical approach of AKT\/mTOR pathway and p-STAT3 in mycosis fungoides. J. Am. Acad. Dermatol. 69, 375\u2013384. https:\/\/doi.org\/10.1016\/j.jaad.2013.04.027 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"52544_CR75","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1182\/blood-2007-06-095182","volume":"111","author":"M Marzec","year":"2008","unstructured":"Marzec, M. et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4\u2009+\u2009T lymphocytes. Blood 111, 2181\u20132189. https:\/\/doi.org\/10.1182\/blood-2007-06-095182 (2008).","journal-title":"Blood"},{"key":"52544_CR76","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41375-018-0305-8","volume":"33","author":"C Cristofoletti","year":"2019","unstructured":"Cristofoletti, C. et al. Blood and skin-derived Sezary cells: Differences in proliferation-index, activation of PI3K\/AKT\/mTORC1 pathway and its prognostic relevance. Leukemia 33, 1231\u20131242. https:\/\/doi.org\/10.1038\/s41375-018-0305-8 (2019).","journal-title":"Leukemia"},{"key":"52544_CR77","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","volume":"125","author":"MD Blunt","year":"2015","unstructured":"Blunt, M. D. et al. The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E\u00b5-TCL1 mouse model. Blood 125, 4032\u20134041. https:\/\/doi.org\/10.1182\/blood-2014-11-610329 (2015).","journal-title":"Blood"},{"key":"52544_CR78","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1600-0625.2010.01102.x","volume":"19","author":"M Kremer","year":"2010","unstructured":"Kremer, M., Sliva, K., Klemke, C. D. & Schnierle, B. S. Cutaneous T-cell lymphoma cells are sensitive to rapamycin. Exp. Dermatol. 19, 800\u2013805. https:\/\/doi.org\/10.1111\/j.1600-0625.2010.01102.x (2010).","journal-title":"Exp. Dermatol."},{"key":"52544_CR79","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1053\/hupa.2000.20370","volume":"31","author":"KF Izban","year":"2000","unstructured":"Izban, K. F. et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: Implications for apoptosis resistance and pathogenesis. Hum. Pathol. 31, 1482\u20131490. https:\/\/doi.org\/10.1053\/hupa.2000.20370 (2000).","journal-title":"Hum. Pathol."},{"key":"52544_CR80","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/ng.3370","volume":"47","author":"A Ungewickell","year":"2015","unstructured":"Ungewickell, A. et al. Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2. Nat. Genet. 47, 1056\u20131060. https:\/\/doi.org\/10.1038\/ng.3370 (2015).","journal-title":"Nat. Genet."},{"key":"52544_CR81","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/exd.14026","volume":"28","author":"B Chen","year":"2019","unstructured":"Chen, B., Zheng, Y., Zhu, J. & Liang, Y. SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-\u03baB pathway in mycosis fungoides. Exp. Dermatol. 28, 1279\u20131288. https:\/\/doi.org\/10.1111\/exd.14026 (2019).","journal-title":"Exp. Dermatol."},{"key":"52544_CR82","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/s41375-018-0066-4","volume":"32","author":"F Gallardo","year":"2018","unstructured":"Gallardo, F. et al. Novel phosphorylated TAK1 species with functional impact on NF-\u03baB and \u03b2-catenin signaling in human Cutaneous T-cell lymphoma. Leukemia 32, 2211\u20132223. https:\/\/doi.org\/10.1038\/s41375-018-0066-4 (2018).","journal-title":"Leukemia"},{"key":"52544_CR83","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1541-7786.Mcr-10-0368","volume":"9","author":"A Juvekar","year":"2011","unstructured":"Juvekar, A. et al. Bortezomib induces nuclear translocation of I\u03baB\u03b1 resulting in gene-specific suppression of NF-\u03baB\u2014Dependent transcription and induction of apoptosis in CTCL. Mol. Cancer Res. 9, 183\u2013194. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-10-0368 (2011).","journal-title":"Mol. Cancer Res."},{"key":"52544_CR84","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","volume":"107","author":"A Sors","year":"2006","unstructured":"Sors, A. et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107, 2354\u20132363. https:\/\/doi.org\/10.1182\/blood-2005-06-2536 (2006).","journal-title":"Blood"},{"key":"52544_CR85","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3892\/or.2016.4669","volume":"35","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z. et al. Curcumin inhibits tumor epithelial-mesenchymal transition by downregulating the Wnt signaling pathway and upregulating NKD2 expression in colon cancer cells. Oncol. Rep. 35, 2615\u20132623. https:\/\/doi.org\/10.3892\/or.2016.4669 (2016).","journal-title":"Oncol. Rep."},{"key":"52544_CR86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jnutbio.2016.12.021","volume":"44","author":"VK Sirohi","year":"2017","unstructured":"Sirohi, V. K. et al. Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells. J. Nutr. Biochem. 44, 60\u201370. https:\/\/doi.org\/10.1016\/j.jnutbio.2016.12.021 (2017).","journal-title":"J. Nutr. Biochem."},{"key":"52544_CR87","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5114\/pdia.2015.48034","volume":"32","author":"J Maj","year":"2015","unstructured":"Maj, J. et al. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides. Postepy Dermatol. Alergol. 32, 437\u2013442. https:\/\/doi.org\/10.5114\/pdia.2015.48034 (2015).","journal-title":"Postepy Dermatol. Alergol."},{"key":"52544_CR88","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jid.2020.06.034","volume":"141","author":"A Aronovich","year":"2021","unstructured":"Aronovich, A. et al. Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12\/CXCR4. J. Invest. Dermatol. 141, 619-627.e612. https:\/\/doi.org\/10.1016\/j.jid.2020.06.034 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"52544_CR89","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","volume":"107","author":"MG Narducci","year":"2006","unstructured":"Narducci, M. G. et al. Skin homing of S\u00e9zary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV. Blood 107, 1108\u20131115. https:\/\/doi.org\/10.1182\/blood-2005-04-1492 (2006).","journal-title":"Blood"},{"key":"52544_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098075","author":"ZA Bordeaux","year":"2023","unstructured":"Bordeaux, Z. A. et al. Differential response of mycosis fungoides cells to vorinostat. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24098075 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52544_CR91","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/jco.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen, E. A. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109\u20133115. https:\/\/doi.org\/10.1200\/jco.2006.10.2434 (2007).","journal-title":"J. Clin. Oncol."},{"key":"52544_CR92","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00128071-200001040-00006","volume":"1","author":"MN Lowe","year":"2000","unstructured":"Lowe, M. N. & Plosker, G. L. Bexarotene. Am. J. Clin. Dermatol. 1, 245\u2013250. https:\/\/doi.org\/10.2165\/00128071-200001040-00006 (2000) (Discussion 251-242).","journal-title":"Am. J. Clin. Dermatol."},{"key":"52544_CR93","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279\u20133290. https:\/\/doi.org\/10.1038\/sj.onc.1210421 (2007).","journal-title":"Oncogene"},{"key":"52544_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101618","author":"C Braicu","year":"2019","unstructured":"Braicu, C. et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers https:\/\/doi.org\/10.3390\/cancers11101618 (2019).","journal-title":"Cancers"},{"key":"52544_CR95","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","volume":"47","author":"AC da Silva Almeida","year":"2015","unstructured":"da Silva Almeida, A. C. et al. The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome. Nat. Genet. 47, 1465\u20131470. https:\/\/doi.org\/10.1038\/ng.3442 (2015).","journal-title":"Nat. Genet."},{"key":"52544_CR96","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"Choi, J. et al. Genomic landscape of cutaneous T cell lymphoma. Nat. Genet. 47, 1011\u20131019. https:\/\/doi.org\/10.1038\/ng.3356 (2015).","journal-title":"Nat. Genet."},{"key":"52544_CR97","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/jid.2011.254","volume":"132","author":"WM Lin","year":"2012","unstructured":"Lin, W. M. et al. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J. Invest. Dermatol. 132, 188\u2013197. https:\/\/doi.org\/10.1038\/jid.2011.254 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"52544_CR98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1476-4598-13-95","volume":"13","author":"Y Qu","year":"2014","unstructured":"Qu, Y. et al. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1. Mol. Cancer 13, 95. https:\/\/doi.org\/10.1186\/1476-4598-13-95 (2014).","journal-title":"Mol. Cancer"},{"key":"52544_CR99","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.celrep.2015.05.004","volume":"11","author":"KK Brown","year":"2015","unstructured":"Brown, K. K., Montaser-Kouhsari, L., Beck, A. H. & Toker, A. MERIT40 Is an Akt substrate that promotes resolution of DNA damage induced by chemotherapy. Cell Rep. 11, 1358\u20131366. https:\/\/doi.org\/10.1016\/j.celrep.2015.05.004 (2015).","journal-title":"Cell Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52544-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T06:05:20Z","timestamp":1705989920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52544-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52544"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52544-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. S.G. Kwatra is an advisory board member\/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. West is an officer of and Director at Genzada Pharmaceuticals. The remaining authors have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1955"}}